They noticed that, despite the equal downregulation of phosphorylated CDC2, a target of WEE1 kinase, treatment with the WEE1 inhibitor significantly reduced the cell viability and increased the DNA damage, just in LKB1-null NSCLC cell lines, in an AMPK-independent way (Figure 4). This evidence concerns the gene WEE1 and non-small cell lung carcinoma.